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1 A Multi-Afﬁliation Research Group for NIRF (http:/As predicted by systems biology, a paradigm shift will emerge through the integration of informa-
tion about different layers of cellular processes. The cell cycle network is at the heart of the cellular
computing system, and orchestrates versatile cellular functions. The NIRF/UHRF2 ubiquitin ligase is
an ‘‘intermodular hub’’ that occupies a central position in the network, and facilitates coordination
among the cell cycle machinery, the ubiquitin–proteasome system, and the epigenetic system. NIRF
interacts with cyclins, CDKs, p53, pRB, PCNA, HDAC1, DNMTs, G9a, methylated histone H3 lysine 9,
and methylated DNA. NIRF ubiquitinates cyclins D1 and E1, and induces G1 arrest. The NIRF gene
is frequently lost in tumors and is a candidate tumor suppressor, while its paralog, the UHRF1 gene,
is hardly altered. Thus, investigations of NIRF are essential to understand the entire biological sys-
tems. Through integration of the enormous information ﬂows, NIRF may contribute to the coupling
between the cell cycle network and the epigenetic landscape. We propose the new paradigm that
NIRF produces the extreme diversity in the network wiring that helps the diversity of Waddington’s
canals.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Introduction
An organism is a highly complicated ‘‘system’’ that is con-
structed through interactions of a large number of distinct compo-
nent subsystems [1]. Systems biology predicts that the properties
of a whole biological network are not a simple extension of itsal Societies. Published by Elsevier
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/www.nirf.jp).parts, but instead exhibit a new ‘‘emergent’’ state that is totally
different from those of the individual subnetwork modules [2].
The pursuit of these novel properties will provide new objectives,
new methodologies, and new insights, which will result in a
paradigm shift in biomedical sciences.
The Np95/ICBP90-like RING ﬁnger protein (NIRF) ubiquitin li-
gase, which is also called ubiquitin-like with PHD and ring ﬁnger
domains 2 (UHRF2), occupies a central position in the cell cycle
network, and has the capacity to ubiquitinate both cyclins D1
and E1 [3]. It is also an ‘‘intermodular hub’’ protein that connects
the cell cycle machinery, the ubiquitin–proteasome system, and
the epigenetic system, and can thus be expected to provide the ba-
sis for a new paradigm in the next few years. In sharp contrast to
its paralog ubiquitin-like with PHD and ring ﬁnger domains 1
(UHRF1), the NIRF gene is frequently lost in tumors [3], and will at-
tract particular attention with respect to its relevance to tumor
pathophysiology.
Here, we summarize the current knowledge about the biologi-
cal properties of NIRF, with a focus on its linkage with tumors,B.V. Open access under CC BY-NC-ND license. 
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network.
2. Overview
The cell cycle network, a signaling network that governs cell cy-
cle progression, is positioned at the heart of the cellular informa-
tion processing system.
Into this network, a multitude of information such as mitogenic
stimuli, survival signals, stress conditions, epigenetic information,
and nutrient statuses converge from the outside and inside of cells
[4]. The network is a highly sophisticated system comprising large
numbers of network modules that integrates the ﬂood of informa-
tion and makes appropriate decisions, thereby orchestrating many
functional modules that direct cell proliferation, differentiation,
stress management, senescence, and survival [4]. Defects in the
proper coordination among many network modules cause various
cellular dysfunctions, such as cell cycle deregulation and genomic
instability, ultimately leading to the development of diseases,
including cancer. However, the network architecture and molecu-
lar basis that ensure the correct functioning of the network as a
sophisticated computing system are largely unknown.
Recent systems biology analyses have revealed the general
properties of the information networks underpinning complex bio-
logical systems. While most proteins have only a few interacting
partners, a small number of ‘‘hub’’ proteins have a very large num-
ber of partners [5]. This ‘‘scale-free’’ property indicates the central-
ity and importance of the hub proteins. In fact, many hub proteins
are essential for the viability of organisms [6]. Each hub protein
serves as a functional and structural core of an individual module,
which comprises a group of proteins related to one another in their
interaction partners, functions, or expression proﬁles. The whole
biological network is not constructed as a random network, but
as an ordered assembly of network modules. Of note, there is a
hierarchical order among the different modules [5], which also
means a hierarchy among the hub proteins. Furthermore, the hub
proteins are classiﬁed into intramodular hubs (party hubs) and
intermodular hubs (date hubs) [7,8]. Intramodular hubs interact
with their partners simultaneously, and act inside functional mod-
ules. In contrast, intermodular hubs bind their different partners
asynchronously, and organize the proteome by connecting the net-
work modules to one another, thereby contributing to the mainte-
nance of the integrity and functions of the whole network [7]. As a
result, mutations of intermodular hubs lead to alterations in the
modularity of the whole network, causing serious defects in cellu-
lar functions. Importantly, intermodular hubs are frequently asso-
ciated with tumorigenesis [9]. Therefore, one of the main streams
of current systems biology is to identify the intermodular hubs
with the highest hierarchy level, and to reveal their relevance to
diseases (particularly cancer), followed by assessment of their
availability as drug targets.
Information processing by the cell cycle network is chieﬂy car-
ried out within the G1 period of the cell cycle [4]. Through the inte-
gration of many signals, the network computes an appropriate
cellular decision for whether to progress through the G1/S bound-
ary, or progress toward alternative cell fates, e.g., differentiation,
death, or senescence. According to the above considerations in sys-
tems biology, we can expect the existence of an intermodular hub
that is involved in the multifaceted cellular decision in the G1
phase. Importantly, defects in G1 control are essential for tumori-
genesis [10]. Therefore, the putative intermodular hub involved in
G1 control would be intimately linked to tumorigenesis.
The ubiquitin–proteasome system and the epigenetic system
are two representative network modules that participate in the
cellular decision through the regulation of large numbers of
genes by inﬂuencing their transcription, translation, and post-translational modiﬁcations [11,12]. Thus, it is possible that the
aforementioned intermodular hub may be related to these sys-
tems. The discovery of such a presumptive intermodular hub will
bring about a great paradigm shift in biomedical sciences.
Modern molecular biology has established the intimate rela-
tionships between the cell cycle network and serious human dis-
eases, especially cancer. However, there have been few
indications of the network architecture and molecular properties
underlying the higher computation functions of the network. For
the above reasons, we attempted to identify a new cell cycle gene,
with consideration of the probability of the existence of an un-
known multifunctional gene involved in the cellular decisions to-
ward various directions.3. Molecular characterization of NIRF
3.1. Cloning of NIRF cDNA
The ubiquitin–proteasome system plays key roles in virtually all
cellular activities by tightly regulating the degradation of a large
set of proteins [11]. This system cooperates with the cell cycle
machinery as a major network module, thereby contributing to cell
cycle regulation and multiple cellular decision processes. Consider-
ing the possibility that the putative determination factor may be
related to the ubiquitin–proteasome system, we searched for a nu-
clear protein exhibiting a physical interaction with the ubiquitina-
tion-prone protein, PEST proteolytic signal-containing nuclear
protein (PCNP), which was newly identiﬁed at that time [13].
PCNP is an abundant nuclear protein containing two remark-
able PEST sequences, which are rich in proline (P), glutamic acid
(E), serine (S), and threonine (T). PEST sequences generally confer
susceptibility to ubiquitin-mediated proteolysis [14]. Many PEST
proteins in the nucleus (e.g., c-Myc, p53, cyclin D1, and cyclin
E1) play important regulatory roles in various processes including
cell cycle control. We observed that knockdown of PCNP by RNA
interference (RNAi) treatment signiﬁcantly reduced cell prolifera-
tion (unpublished data), while the PCNP mRNA level was reduced
upon cell differentiation [15].
We performed a yeast two-hybrid screening to search for pro-
teins interacting with PCNP. We found NIRF, on the basis of its
complex formation with PCNP [16]. We further revealed that NIRF
is a ubiquitin ligase and ubiquitinates PCNP [13].
3.2. Structural characteristics of NIRF
NIRF is a nuclear protein with 802 amino acid residues. NIRF is a
multidomain protein that shows high structural similarity to
UHRF1, which is also called Np95 and ICBP90 (Fig. 1A). NIRF and
UHRF1 share at least ﬁve functional domains, namely the ubiqui-
tin-like (UBL) domain (also called NIRF_N domain) at the N-termi-
nus, tandem Tudor domain (TTD), plant homeodomain (PHD)
ﬁnger domain, SET and RING associated (SRA) domain, and really
interesting new gene (RING) ﬁnger domain at the C-terminus. Re-
cent X-ray crystallographic and NMR analyses have revealed the
structures of these domains and their recognition modes for the
modiﬁcation statuses of DNA and histone H3 lysine residues.
3.2.1. NIRF_N domain (UBL domain)
Although many UBL domain-containing proteins interact with
the 26S proteasome, which is responsible for ubiquitin-mediated
intracellular proteolysis, it has not been structurally clariﬁed how
the UBL domains in NIRF and UHRF1 are involved in these interac-
tions. Ubiquitin forms a ﬁve-stranded b-sheet with a single helix. It
is assumed that most UBL domains, including those in NIRF and
UHRF1, could have a similar ubiquitin fold [17] (Fig. 1B).
Fig. 1. NIRF and UHRF1 are multidomain proteins providing diverse recognition platforms. (A) Domain organizations of NIRF (UHRF2) and UHRF1, including a ubiquitin-like
(UBL) domain, tandem Tudor domain (TTD), plant homeodomain (PHD) ﬁnger domain, SET and RING associated (SRA) domain, and really interesting new gene (RING) ﬁnger
domain. The domain structures were created using DOG1.0 software [119]. (B) Solution structure of the human NIRF UBL domain (PDB code: 1WY8) and crystal structure of
the human UHRF1 UBL domain (PDB code 2FAZ). (C) Solution structure of the human TTD in complex with histone H3 trimethylated on lysine 9 (H3K9me3) (PDB ID: 2L3R)
[19]. (D) Solution structure of the human NIRF PHD ﬁnger domain (PDB ID: 2E6S) and crystal structure of the human UHRF1 PHD ﬁnger domain in complex with unmodiﬁed
histone H3 peptide (H3R2) (PDB ID: 3SOU) [22]. (E) Crystal structures of the human NIRF SRA domain (PDB ID: 3OLN) and of the human UHRF1 SRA domain in complex with
hemimethylated DNA (PDB ID: 3CLZ) [25]. (F) Crystal structures of the human NIRF RING ﬁnger domain (PDB code 1Z6U) and the human UHRF1 RING ﬁnger domain (PDB ID:
3FL2). In all cases, the proteins and bound ligands are shown in ribbon and stick models, respectively, and Zn ions are shown in gray spheres. The ﬁgure was prepared using
Pymol software (http://www.pymol.org/).
1572 T. Mori et al. / FEBS Letters 586 (2012) 1570–15833.2.2. Tandem Tudor domain (TTD)
NIRF contains a TTD. Although the TTD itself does not possess
high binding afﬁnity for histone H3 tail peptides harboring di-
and tri-methylated lysine 9 (H3K9me2/me3), the combined TTD–
PHD region binds to H3K9me2/me3-containing peptides with high
afﬁnity [18]. Recent solution NMR and crystallographic studies
have revealed that the two Tudor domains in UHRF1 are tightly
packed to each other [19]. Each Tudor domain has a ﬁve-stranded
b-barrel fold seen in various histone-binding proteins, such as p53binding protein 1 (53BP1), which binds to histone H4K20me2 [20].
In the TTD–histone peptide complex, the ﬁrst Tudor domain recog-
nizes histone H3K9me3 through a conserved aromatic cage
(Fig. 1C). No structural information for the NIRF TTD is currently
available.
3.2.3. PHD ﬁnger domain
A PHD ﬁnger is a small domain that is often found in nuclear
proteins involved in chromatin-mediated gene regulation. Many
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histone tails. Although the PHD ﬁnger of NIRF does not possess
binding afﬁnity toward histone H3 tail peptides, the combined
TTD–PHD region of NIRF has higher binding afﬁnity to H3K9me2/
me3 than the single TTD as described above [18]. This cooperation
is attributed to the highly conserved linker region that connects
the TTD and PHD ﬁnger. In contrast, the same authors showed that
the combined TTD–PHD region of UHRF1 does not exhibit en-
hanced binding to the histone H3 peptides [18]. However, Xie et
al. [21] showed that the combined TTD–PHD domains of UHRF1
act together to recognize H3K9me3. Therefore, there is still room
for argument regarding the function of the TTD–PHD region. The
PHD ﬁnger of UHRF1 is known to interact with unmodiﬁed histone
H3R2 (Fig. 1D). The binding mode was revealed from the crystal
structure of the UHRF1 PHD ﬁnger in a complex with the histone
H3 peptide [22]. A guanidinium group of the unmodiﬁed histone
H3R2 residue forms extensive intermolecular contacts with the
negatively charged surface groove on the PHD ﬁnger.
3.2.4. SRA domain
Although it remains controversial, the NIRF SRA domain may be
involved in interactions with hemimethylated DNA [23]. The crys-
tal structure of the UHRF1 SRA domain was reported in a complex
with double-stranded DNA containing C5-methylated cytosine in
one strand and unmethylated cytosine in the other strand [24–
26]. The SRA domain contains two twisted b-sheets packed to-
gether, and binds to DNA using the basic concave surface. The most
characteristic feature of the UHRF1 SRA domain is recognition of a
ﬂipped methylated cytosine (Fig. 1E). In the crystal structure, the
methylated cytosine is completely ﬂipped out from the DNA dou-
ble helix, and the methyl group is packed against a small cavity
within a conserved pocket in the SRA domain. Base ﬂipping is a
conserved mechanism that is often used by DNA/RNA-modifying
enzymes. The SRA domain is the ﬁrst identiﬁed non-enzymatic se-
quence-speciﬁc DNA-binding protein that uses base ﬂipping in its
interaction with DNA. The detailed ligand-binding mode of the
NIRF SRA domain has not been reported, although the crystal struc-
ture of the ligand-free SRA domain is available. According to a re-
port, NIRF moderately binds to fully methylated DNA in addition to
its strong binding to hemimethylated DNA, similar to the case for
UHRF1 [23].
3.2.5. RING ﬁnger domain
A RING ﬁnger domain is a small zinc-binding domain that often
possesses ubiquitin ligase activity. The RING ﬁnger domain con-
tains two zinc ions in a unique ‘‘cross-brace’’ arrangement through
a deﬁned motif composed of cysteine and histidine residues
(Fig. 1F). This arrangement endows the RING ﬁnger domain with
a globular conformation, characterized by a central a-helix and
variable-length loops separated by several small b-strands [27].
Iwata et al. [28] revealed that NIRF ubiquitinates nuclear polyglu-
tamine aggregates via its RING ﬁnger domain. The exact amino acid
residues in this domain of NIRF that determine the substrate spec-
iﬁcity have not been identiﬁed.
3.3. Subcellular localization and expression proﬁles of NIRF
NIRF is enriched at pericentromeric heterochromatin indepen-
dently of the cell cycle, as described later in Section 5.3 [23]. This
subcellular localization depends on an intact TTD and histone
H3K9me3.
NIRF is ubiquitously expressed in almost all tissues (http://biog-
ps.org; [29]) (Fig. 2, left). NIRF is upregulated during the course of
differentiation [18], and expressed in terminally differentiated tis-
sues including the brain, lung, and kidney (unpublished data;[18,29]). These expression proﬁles are in sharp contrast to those
of UHRF1. UHRF1 is exclusively expressed in proliferating and/or
undifferentiated cells, but not in quiescent cells [30–32] (Fig. 2,
right), and is downregulated accompanied by differentiation
[18,31–33]. The reciprocal expression between NIRF and UHRF1
suggests different functional roles of these proteins in differentia-
tion [18]. These observations are consistent with the concept that
they have opposing functions in cell proliferation [30,34].
B- and T-lymphocytes have speciﬁc properties in that they are
subject to somatic recombination of antigen receptor genes during
development. Both types of lymphocytes comprise many different
lineages and subsets of cells with differing sets of active transcrip-
tion networks, reﬂecting their different epigenetic landscapes [35].
Interestingly, there is a prominent difference in the expression pro-
ﬁles of NIRF and UHRF1 in lymphoid cells (Fig. 2). NIRF is highly ex-
pressed in lymph nodes, especially in germinal center B cells [36],
as well as in CD4+ T cells, CD8+ T cells, and CD4+CD25+ regulatory T
cells [29]. In contrast, UHRF1 is highly expressed in the thymus,
but not in lymph nodes [32]. UHRF1 shows very little, if any,
expression in CD4+ T cells, CD8+ T cells, and CD4+CD25+ regulatory
T cells [29]. These characteristic expression proﬁles with large dif-
ferences in different lineages may be associated with the epige-
netic diversity in lymphocytes. Otherwise, they may have a
relationship with the somatic recombination event that is accom-
panied by gross rearrangement of the genome and epigenome.
4. NIRF occupies a central position in the cell cycle network
Recently, we found that NIRF interacts with core cell cycle pro-
teins including cyclins (A2, B1, D1, and E1), cyclin-dependent ki-
nases (CDK2, CDK4, and CDK6), retinoblastoma 1 protein (pRB),
tumor protein p53 (p53), and proliferating cell nuclear antigen
(PCNA). Since all of these interactors are core components of the
cell cycle machinery, NIRF must have a close relationship with cell
cycle control. Thus, NIRF is considered to be a novel core compo-
nent of the cell cycle machinery [3].
Notably, all of these interactors are themselves hub proteins
that have many interacting partners of their own, and form indi-
vidual network modules (Fig. 3). NIRF is positioned at the center
of these modules, thereby connecting the individual modules to
one another. When a network analysis was carried out for this NIRF
interaction network, the calculated multiple centrality indexes for
NIRF, i.e., betweenness centrality, closeness centrality, and degree
centrality, were all signiﬁcantly high [3]. In addition to these ﬁnd-
ings, the expression proﬁles of the NIRF interactors, namely cyclins,
CDKs, pRB, p53, and PCNA, were mutually distinct, indicating that
NIRF is an ‘‘intermodular hub’’ of the cell cycle network with func-
tional as well as structural centralities. Thus, NIRF occupies a crit-
ical position within the hierarchical modular architecture of the
network [3]. Therefore, NIRF is presumed to be involved in multi-
faceted cellular processes as described earlier in Section 2.
The cell cycle network plays very important roles in coordinat-
ing the activities of diverse subnetwork modules to ensure the
proper execution of cell cycle events. In addition to the cell cycle
machinery, the ubiquitin–proteasome system and the epigenetic
system constitute the two major functional modules of the net-
work. In this regard, NIRF has a characteristic multidomain compo-
sition that mediates interactions with these systems. Therefore, we
propose that NIRF constitutes a nodal point in the cell cycle net-
work that is particularly involved in coordination among the cell
cycle machinery, the ubiquitin–proteasome system, and the epige-
netic system.
Taken together, these situations reinforce the concept that NIRF
is a central factor of the whole network system of the cell. In agree-
ment with this notion, it is becoming increasingly clear that defects
Fig. 2. NIRF and UHRF1 are expressed in different tissues and organs [29]. mRNA expression values for each gene were standardized into Z-scores with barcode approach
[120]. A Z-score more of than 5 means that the gene is expressed in that tissue. NIRF is ubiquitously expressed in most differentiated tissues, while UHRF1 is mainly expressed
in proliferating and/or undifferentiated tissues. With respect to the lymphatic system, NIRF is highly expressed in lymph nodes as well as different subsets of B and T cells. In
contrast, UHRF1 is not expressed in lymph nodes except in germinal center B cells (centrocytes and centroblasts).
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tumorigenesis [3]. Thus, the next major target of this research ﬁeld
will be to investigate how NIRF contributes to the proper coupling
between the modules around NIRF, and how defects in this coordi-
nation function are associated with various human diseases, espe-
cially cancer.5. NIRF mediates interactions between the network modules
In this section, we describe the three network modules with
interactions mediated by NIRF, i.e., the cell cycle machinery, the
ubiquitin–proteasome system, and the epigenetic system. In addi-
tion, we discuss the possible interrelationships between these
modules in light of the systems-level integration of the network
modules.5.1. The cell cycle machinery
The cell cycle machinery is the central module of the cell cycle
network. It is composed of multiple combinations of cyclin/CDK
complexes, where each cyclin is the activation subunit of its cog-
nate CDK [37]. Meanwhile, the activity of the cell cycle machinery
is under the highest control, since deregulation of the machinery
often leads to the development of cancer [10].
The cell cycle is a complex process whereby DNA replication
and mitotic cell division take place, and periodic oscillations in
the CDK activities are essential for correct progression through
the cell cycle as well as maintenance of the genome integrity
[38,39]. The oscillations in the CDK activities are brought about
by ﬂuctuations in the cyclin abundances, which are regulated at
the levels of transcription and proteolysis at particular time pointsof the cell cycle [39,40]. The different cyclin/CDK complexes phos-
phorylate distinct groups of substrates in each cell cycle phase,
thereby providing a driving force for the progression of cell cycle
events [41]. The G1 cyclins (D and E) are important in the G1/S
transition, where they determine whether a cell enters another
round of cell division [37,42,43]. In response to mitogenic stimuli,
the amount of cyclin D1, a prototypical cyclin D, is increased and
forms complexes with CDK4/6, which then target pRB for phos-
phorylation [43]. Upon phosphorylation, pRB loses its ability to in-
hibit G1/S progression and releases the transcription factor E2F
[44,45]. As an essential protein for cell cycle progression, E2F in-
creases the amount of cyclin E, which binds to CDK2 and triggers
the phosphorylation of many substrates, including pRB, required
for G1/S progression [46]. Among the mitotic cyclins (A and B), cy-
clin A is expressed from S phase to early M phase while cyclin B is
expressed from G2 phase to M phase. Cyclin A forms complexes
with CDK1 and CDK2, while cyclin B forms a complex with CDK1.
The cyclin A/CDK2 complex controls DNA replication, while cyclin
A/CDK1 and cyclin B/CDK1 complexes cooperate with each other
during the initiation and completion of mitotic cell division [47].
For appropriate modulation of the cell cycle machinery activity,
the cell cycle network performs a complex process of computation.
The network integrates diverse inputs (e.g., growth factor stimuli,
matrix attachment, nutrient sufﬁciency, checkpoint status, and
epigenetic landscape), and creates correct outputs by affecting,
for example, the transcription, phosphorylation, and ubiquitination
of cell cycle proteins including cyclins, CDKs, and CDK inhibitors
[4]. This integration process involves two different layers of regu-
latory networks that act cooperatively: the protein–protein inter-
action network (PPIN) and the gene regulatory network (GRN)
[48]. The PPIN depends on various modes of interactions (e.g., sig-
naling, regulatory, or biochemical) between the cell cycle proteins.
Fig. 3. The NIRF protein–protein interaction network. NIRF interacts with the core cell cycle proteins (cyclin A2, cyclin B1, cyclin D1, cyclin E1, pRB, and p53) and other
nuclear proteins. These core cell cycle proteins are hub proteins with many interacting partners, and thereby constitute individual network modules. NIRF is positioned at the
center of these modules, thereby connecting the modules to one another. The symbols used are as follows: yellow, cyclins; yellow–green, CDKs; blue, two major tumor
suppressors; green, NIRF-interacting proteins retrieved from a database [121]. The thicker black lines indicate interactions demonstrated by more than two methods.
(Reproduced with permission from reference [3]).
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ments with other substances in the cell, thereby regulating the
transcription of the cell cycle genes [49]. NIRF participates in both
the PPIN and GRN through its direct interactions with the cell cycle
proteins and by affecting the transcription of the cell cycle genes,
respectively [3,50]. This two-sided function of NIRF makes it a
highly attractive molecule that may play a critical role in imposing
strict controls on the cell cycle machinery.
On the one hand, NIRF takes part in protein–protein interac-
tions with the core components of the cell cycle machinery, there-
by deﬁning a crucial nodal point of the PPIN (Fig. 3) [3]. To our
knowledge, no other ubiquitin ligases have been shown to exhibit
such wide accessibility to both cell cycle-promoting factors (cyc-
lins A, B, D, and E, CDK2, CDK4, CDK6, and PCNA) and cell cycle-
inhibitory tumor suppressors (pRB and p53) [3]. NIRF interacts
with both the G1 cyclins (D1 and E1) and the mitotic cyclins (A2
and B1), suggesting versatile roles for NIRF in a wide range of cell
cycle phenomena, such as cell cycle entry, restriction (R)-point
transition, DNA replication, mitotic cell division, and checkpoint
control.
On the other hand, NIRF has the potential to be engaged in the
GRN, through complex formation with chromatin, chromatin-asso-
ciated proteins, and/or DNA [3,18,23]. The two major tumor sup-
pressors, pRB and p53, are representative chromatin-associatedproteins that affect a vast array of target genes. These tumor sup-
pressors cooperatively impose strict surveillance of the activities
of the cell cycle machinery to hinder cells from undergoing malig-
nant transformation [10]. NIRF interacts with these tumor suppres-
sors as well as two different G1 cyclins. All of these molecules are
important regulators of the G1 checkpoint system, which is the
most critical barrier for inhibiting cell transformation [51]. These
interactions suggest intense functional interplay between NIRF
and these G1 control proteins to ensure the precise functioning
of the G1 checkpoint system. NIRF may cooperate with pRB and
p53 to effectively induce G1 arrest in response to various insults
that trigger DNA damage.
Since UHRF1 has a similar domain composition to NIRF, it may
also interact with the cell cycle machinery. In contrast to NIRF,
UHRF1 promotes G1/S transition, and p53 downregulates the
expression levels of UHRF1 [52]. Currently, it is considered that
UHRF1 regulates transcription through recognition of chromatin
marks and interactions with proteins that modulate the histone
modiﬁcation status such as HDAC1 and G9a [53], but not through
interactions with the cell cycle ‘‘hub’’ proteins like NIRF [3]. How-
ever, further analyses are required.
Finally, contrary to the sequence of events whereby NIRF regu-
lates cyclin/CDK complexes, NIRF may be subject to regulation via
phosphorylation by CDKs. Indeed, NIRF is phosphorylated by the
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that UHRF1 is phosphorylated by several kinases including protein
kinase A [54], casein kinase 2 [55], cyclin A2/CDK2 complex [56],
and cyclin B/CDK1 complex [57]. Phosphorylation of UHRF1 by
the cyclin A2/CDK2 complex is required for zebraﬁsh embryogen-
esis [56], and M phase phosphorylation of UHRF1, possibly by
the cyclin B/CDK1 complex, regulates its physical association with
the deubiquitinase USP7 and stability, thereby contributing to cell
cycle progression [57]. Phosphorylation by CDKs may represent an
important input mechanism for both NIRF and UHRF1 and their
network activities.
5.2. The ubiquitin–proteasome system
The ubiquitin-mediated regulation of the cell cycle machinery
underlies numerous cellular decision processes. Notably, virtually
all of the core cell cycle proteins are subject to control via ubiqui-
tination, demonstrating that the ubiquitin–proteasome system is a
major network module that occupies a pivotal position in the cell
cycle network. Not surprisingly, there is a strong association be-
tween deregulated ubiquitination and human cancers [58–60].
The ubiquitin–proteasome system targets cyclins for regulated
destruction, which is critical for the maintenance of orderly pro-
gression through the cell cycle [58,61]. Ubiquitination is catalyzed
through successive reactions of three enzymes: a ubiquitin-acti-
vating enzyme (E1), a ubiquitin-conjugating enzyme (E2), and a
ubiquitin ligase (E3). The polyubiquitinated cyclins are then re-
cruited to a large ATP-dependent protease complex called the
26S proteasome, where they are subject to rapid destruction
[11]. Among the components of the ubiquitination system, the E3
ubiquitin ligase is the primary determinant of target recognition
depending on its binding capacity to the substrate [62]. The G1
cyclins and the mitotic cyclins are basically degraded by the
S-phase kinase-associated protein 1 (Skp1)/cullin 1 (Cul1)/F-box
protein (SCF) complex and the anaphase-promoting complex/
cyclosome (APC/C), respectively [58,63]. The SCF complexes use
different F-box proteins to recognize distinct substrates, while
the APC/C uses only two substrate adapters to target many sub-
strates [63].
With respect to the association with human cancers, it is most
important to note that impaired ubiquitination of either G1 cyclin
causes its aberrant overexpression, resulting in deregulation of the
G1/S transition and ultimately leading to cancer [59,64]. Therefore,
complete understanding of the ubiquitin ligases for G1 cyclins is of
great importance. According to the classical view, F-box and WD
repeat domain containing 4 (FBXW4), F-box and WD repeat do-
main containing 8 (FBXW8), and F-box protein 31 (FBXO31) target
cyclin D1, while F-box and WD repeat domain containing 7
(FBXW7) recognizes cyclin E [58]. These SCF ubiquitin ligases are
considered to contribute to the control at the G1/S boundary by
promoting the degradation of speciﬁc G1 cyclins. Consistent with
this, FBXW7 is a tumor suppressor whose loss of function is seen
in a number of carcinomas [65].
Surprisingly, however, the identity of the ubiquitin ligase for cy-
clin D1 is still under debate [66,67]. This situation is amazing, be-
came abnormal overexpression of cyclin D1 caused by defective
ubiquitination is one of the most frequent causes of many types
of tumors [43]. Furthermore, it has been demonstrated that neither
SCF nor APC/C complexes contribute to the control of cyclin D1 sta-
bility [67]. This controversy suggests the existence of other ubiqui-
tin ligases that target cyclin D1 [67]. In this context, NIRF is an
example of a single-subunit, non-SCF type ubiquitin ligase for cy-
clin D1.
We found that NIRF is capable of ubiquitinating two different
classes of G1 cyclins, D1 and E1 [3]. In sharp contrast, the SCF ubiq-
uitin ligases are only able to target either cyclin D1 or E, but notboth [58], thereby allowing individual control for each cyclin. To
our knowledge, no other ubiquitin ligases have been reported to
target both G1 cyclins. This particular property suggests a unique
mechanism underlying the substrate recognition by NIRF, which
could provide coordinated regulation at the G1/S boundary. In
addition, this observation highlights a possible characteristic prop-
erty of NIRF as a hub-type ubiquitin ligase targeting multiple sub-
strates for ubiquitination. Thus, in cases with NIRF abnormalities,
the control of both cyclins D1 and E1 may become coincidentally
abrogated, which could readily result in impaired control at the
G1/S boundary. It will be intriguing to clarify whether NIRF is also
capable of targeting other mitotic cyclins for ubiquitination.
The recognition of G1 cyclins by NIRF is characteristic in four
additional respects as follows. First, NIRF is a non-SCF type ubiqui-
tin ligase for cyclin D1 [3]. This is consistent with the recent indi-
cation that there would be a novel ubiquitin ligase targeting cyclin
D1 other than the SCF and APC/C complexes [67]. Second, NIRF rec-
ognizes the G1 cyclins without their phosphorylation [3]. Thus far,
phosphorylation-independent ubiquitination pathways have been
proposed for both cyclins D1 and E, in addition to the well-known
phosphorylation-dependent pathways [68]. Since the SCF ligases
target the G1 cyclins upon phosphorylation of the substrates, the
presence of the phosphorylation-independent pathways further
highlights the involvement of the SCF-independent ubiquitination
mechanisms for both G1 cyclins. Third, NIRF can ubiquitinate the
free forms of G1 cyclins that are not bound to their cognate CDKs
[3]. Again, the presence of ubiquitination pathways for the free
forms of the G1 cyclins has been reported for both cyclins D1
and E. NIRF represents a novel ubiquitin ligase for the free forms
of cyclins D1 and E1, which may serve to regulate the cellular lev-
els of free cyclins. With regard to cyclin E, NIRF binds cyclin E1 and
directly promotes its ubiquitination, while FBXW7 recognizes the
cyclin E protein only when it is phosphorylated by the activated cy-
clin E/CDK2 complex [58,65]. These differences imply that the cel-
lular conditions in which cyclin E is recognized by NIRF or FBXW7
may be different. NIRF would restrict the abundance of cyclin E be-
fore it reaches the maximal level at the G1/S boundary. Contrary to
this, FBXW7 is thought to target phosphorylated cyclin E after the
CDK2 kinase activity reaches the maximal activity, thereby forming
a negative feedback regulation of the cyclin E/CDK2 activity [69].
The physiological relevance of the ubiquitination pathway for free
cyclin D1 remains to be clariﬁed. Fourth, the ubiquitination of cyc-
lins by NIRF takes place in the nucleus (unpublished data). While
the ubiquitination of cyclin E occurs in both the nucleus and cyto-
plasm [70], that of cyclin D1 predominantly takes place in the cyto-
plasm [71]. However, there has been a debate regarding the
subcellular localizations for the ubiquitination and degradation of
cyclin D1 [68]. The SCF ligases ubiquitinate threonine 286
(T286)-phosphorylated cyclin D1 within the cytoplasm and target
it for degradation [71]. Conversely, free cyclin D1 is ubiquitinated
and degraded in the nucleus, independently of T286 [72]. It will
be important to investigate whether NIRF is involved in the phos-
phorylation-independent, intranuclear ubiquitination pathway for
free cyclin D1, and to elucidate the associations, if any, of this path-
way with tumorigenesis.
The other ubiquitination substrates of NIRF include PCNP and
huntingtin, and the latter is described later in Section 6.2.
Finally, UHRF1 ubiquitinates histone H3 [73] and DNA methyl-
transferase 1 (DNMT1) [74]. H3 ubiquitination is linked with the
formation of heterochromatin [75]. On the other hand, ubiquitina-
tion of DNMT1 involves acetylation regulation by Tip60/histone
deacetylase 1 (HDAC1) and ubiquitination regulation by UHRF1/
USP speciﬁc peptidase 7 (USP7), which is also called Herpesvirus-
associated ubiquitin-speciﬁc protease (HAUSP) [74]. These known
targets of NIRF and UHRF1 for ubiquitination are totally different,
suggesting functional differences between the two proteins.
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nents of the cell cycle machinery for ubiquitination, and this will
be interesting to explore in future studies.
5.3. The epigenetic system
Epigenetics refers to heritable changes in phenotype or gene
expression caused by mechanisms other than changes in the
underlying DNA [76]. The epigenetic system regulates DNA meth-
ylation and covalent histone modiﬁcations, which inﬂuence gene
expression, and plays a chief regulatory role in differentiation
and development [77]. On the other hand, this system also regu-
lates cell cycle progression locally by affecting the expression of
individual cell cycle genes, and globally by controlling chromatin
condensation and chromosome segregation [78]. Conversely, the
cell cycle mechanism ensures correct inheritance of epigenetic
information to the daughter cells [78].
In general, proliferation and differentiation are mutually exclu-
sive, although they are cooperatively regulated during the course
of development [79]. This ‘‘proliferation/differentiation switch’’
constitutes a cell cycle checkpoint in the G1 phase [80]. This check-
point is extremely important for normal development, and its
abrogation is the basis for malignant transformation and cancer
development [79]. However, the precise mechanisms of how cells
coordinate this switch still remain unknown. Systems biology
researchers have claimed that Waddington’s theory of develop-
ment as a canalization of the epigenetic landscape shaped by gene
networks will provide clues toward solving this problem [81].
Extrapolating from Waddington’s theory, proliferation and differ-
entiation may be seen as solutions of cross-antagonistic network
modules [76]. In other words, during the course of development,
two cross-antagonistic networks would be working with mutually
reciprocal patterns of expression. Conversely, the anti-correlated
expression proﬁles between two network modules are important
indications of their involvement in the ‘‘switch’’ between the two
different phases of the cell [81]. Indeed, two distinct network mod-
ules exist: the ‘‘proliferation module’’ that accelerates cell prolifer-
ation and the ‘‘differentiation module’’ that promotes cell
differentiation. Importantly, as predicted by the theory, these
cross-antagonistic modules are inversely correlated with each
other at the transcription level [81]. Speciﬁcally, upon differentia-
tion, the ‘‘proliferation module’’ is downregulated while the ‘‘dif-
ferentiation module’’ is upregulated.
In this regard, NIRF and UHRF1 are involved in the GRN as epi-
genetic factors with mutually reciprocal expression proﬁles during
the course of differentiation [18]. UHRF1 is expressed in embryonic
stem cells and downregulated during differentiation, whereas NIRF
is upregulated and highly expressed in differentiated tissues [18].
Moreover, these molecules are not only involved in the GRN, but
also in the PPIN. The concerted actions of these two different layers
of networks are supposed to affect cell proliferation and differenti-
ation in versatile ways. In that case, what is the difference between
the biological roles of the NIRF and UHRF1 gene networks? Is there
any relationship to Waddington’s prediction? Most probably, NIRF
and UHRF1 are multifunctional intermodular hub proteins with
many interaction partners, and thereby behave as the central factor
of each network. Furthermore, each of them would mediate inter-
actions among the cell cycle machinery, ubiquitin–proteasome
system, and epigenetic system. Therefore, the networks may
greatly amplify the original biological activities of each hub protein
residing at the center of the respective network. Accordingly, the
difference between the biological functions of NIRF and UHRF1, if
any, would also be signiﬁcantly ampliﬁed through extensive net-
working. In more detail, the differences in the molecular struc-
tures, functions, or expression proﬁles between the two hub
proteins will bring about considerable differences in the biologicalactivities of the whole network. This will arise from any differences
at the molecular level between the two hub proteins by various
reasons, such as (1) differences in their repertoires of interacting
partners, (2) different outcomes of their interactions even with
the common interacting partners, (3) differences in the proteome
expressed at the time and place of their existence, which cause dif-
ferences in the composition of their protein complexes, (4) genetic
and epigenetic differences in the organization of their promoters,
which affect their expression proﬁles, and (5) prominent differ-
ences between each network in the global architecture and func-
tions caused by points (1 to 4). Thus, even slight differences in
the properties between NIRF and UHRF1 will bring about large dif-
ferences in their physiological functions. Considering the hugeness
of each network, the reciprocally correlated expression of such ver-
satile hub proteins could be the basis of a ‘‘phase transition’’ at the
systems level, for example, the ‘‘proliferation/differentiation
switch’’.
Then, does the above discussion have merit to interpret the
molecular distinction between NIRF and UHRF1? Before discussing
their differences, we brieﬂy summarize the currently available
information for UHRF1. UHRF1 was initially identiﬁed as mouse
protein Np95, which is predominantly expressed in the S phase
in normal thymocytes [31]. UHRF1 is upregulated in various cancer
cells, especially malignant undifferentiated cancer cells with high
proliferation ability [82,83]. Knockdown of UHRF1 expression in
cancer cells signiﬁcantly suppresses cell growth, indicating that
UHRF1 is essential for cancer progression [53]. In S phase, UHRF1
binds to PCNA, recognizes hemi-methylated DNA, which appears
at replication forks, recruits DNMT1 to the sites, and methylates
unmethylated cytosines in the hemi-methylated DNA. Therefore,
UHRF1 plays a fundamental role for the maintenance of DNAmeth-
ylation patterns [24–26,84]. In addition, UHRF1 is involved in DNA
damage control [85], and in the replication and reorganization of
pericentromeric heterochromatin [86]. These observations suggest
that UHRF1 belongs to the ‘‘proliferation module’’, and thereby
drives a wide range of cellular processes that are centrally involved
in cell proliferation. In this connection, the molecular activities of
the genes belonging to the ‘‘proliferation module’’ are directed to-
ward various aspects of proliferation-associated functions [81].
Although UHRF1 has various roles, the cumulative outcomes of
its molecular functions will converge to cell proliferation-associ-
ated activity at the cellular level.
On the other hand, slight differences have been noted between
the molecular structures and functions of NIRF and UHRF1. They
exhibit opposite expression patterns during the course of develop-
ment and tissue distributions. Similar to UHRF1, NIRF is localized
to the pericentric heterochromatin. NIRF interacts with methylated
histone H3 lysine 9 (H3K9) through its TTD–PHD region, and prob-
ably with hemi-methylated DNA through its SRA domain [18]. In
addition, both NIRF and UHRF1 bind to DNA methyltransferases
(DNMT1, DNMT3A, and DNMT3B) and a histone methyltransferase
(G9a) [23]. Despite all these functional conservations, NIRF does
not maintain the DNA methylation status [18,23]. UHRF1 interacts
with DNMT1 in an S phase-dependent manner, while NIRF does
not. In addition, NIRF and UHRF1 neither interact [3,23] nor colo-
calize [23] with each other. Thus, UHRF1 and NIRF are not func-
tionally redundant in terms of DNA methylation maintenance.
Collectively from these observations, the differences in NIRF
and UHRF1 are slight at the molecular level. However, given that
NIRF and UHRF1 each have signiﬁcant centrality in a respective
huge network, even slight differences may lead to large differences
in their systems-level functions. If the differences between NIRF
and UHRF1 are really of physiological importance, and if they rep-
resent the cross-antagonistic modules of the ‘‘differentiation mod-
ule’’ and the ‘‘proliferation module’’, respectively, there will be a
signiﬁcant difference in their relevance to tumors. Indeed,
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considerable differences in their relationships with cancer, as de-
scribed later in Section 6.1.
5.4. Integration of the network modules: involvement in cellular
decisions
We have described the centrality of NIRF in the cell cycle net-
work that mediates interactions among three network modules,
whereby it occupies a pivotal position in the cellular computing
system. Here, we present a hypothesis of how the NIRF gene net-
work may participate in cellular decision processes.
The cell cycle network is a complex ‘‘system’’ constructed from
multiple interactions between many distinct subnetwork modules
[1]. However, the ‘‘emergent’’ properties of the whole network are
not a simple aggregation of those of the constituents. Rather, they
are inherently novel, according to systems biology [2]. NIRF medi-
ates interactions among the three aforementioned modules with
completely distinct properties. This indicates that the molecules
in the network are subject to multiple distinct layers of regulation,
such as phosphorylation, ubiquitination, proteolysis, transcription
regulation, and epigenetic regulation. Such a multidimensional
regulation will allow ﬁne-tuning of the molecular properties of
each component. Eventually, the whole network constructed from
large numbers of these ﬁne-tuned components will exhibit an
emergent state. A striking property of this network is the immense
complexity of the physical and functional interactions between
many regulated components, which will allow the production of
a large amount of distinct functional wiring [87]. Waddington’s
theory demonstrates that to exhibit distinct phenotypes, cells se-
lect the appropriate network modules to be activated, while inac-
tivating other modules [76]. Given that the total number of
genes is limited, reorganization of the network architecture would
be an important means for creating a large amount of different net-
work wiring to manifest versatile phenotypes. As an intermodular
hub, NIRF could be expected to be involved in such a reorganiza-
tion process of the network architecture [3].
The NIRF gene network is assumed to have numerous inputs
and outputs, through multidirectional involvement in the different
network modules. As described, NIRF exhibits a prominent central-
ity in the PPIN [3]. In addition, NIRF is presumed to be involved in
the control of expression of many genes through chromatin and/or
transcriptional regulation [23].
As inputs, many events will cooperatively impact on the molec-
ular properties of NIRF. These events may include the cell cycle-
dependent formation of different protein complexes (e.g., cyclins,
CDKs, pRB, p53, PCNA, DNMT1, HDAC1, and G9a), phosphorylation
by kinases, including CDKs, and modiﬁcation by ubiquitination
(including autoubiquitination [13]). Notably, phosphorylation at
many serines and threonines in NIRF have been reported (http://
www.phosphosite.org; [88]). The phosphorylation of any of these
sites may cause alterations in the molecular characteristics of NIRF.
In addition, NIRF would integrate these different inputs with the
genetic and epigenetic information [3]. To integrate the various
information ﬂows, it would be advantageous for NIRF to be associ-
ated with the chromatin, where the highest priority information
exists. The integration would be performed through reading of
the epigenetic codes under tight cooperation with the many signal-
ing pathways as well as the cell cycle machinery and the ubiqui-
tin–proteasome system.
On the other hand, from NIRF to downstream pathways, two
distinct layers of output would be in operation, i.e., NIRF would
take part in the GRN and PPIN. For the GRN, NIRF may be involved
not only in cell-type-speciﬁc gene regulation through the reading
of various epigenetic marks [23], but also in more general generegulation through cooperation with diverse chromatin-associated
proteins and/or transcription factors, for instance, p53 or pRB.
Moreover, NIRF would be involved in the modiﬁcation of epige-
netic information of histones and DNA, again in intimate cross-talk
with many signaling pathways, the cell cycle machinery, and the
ubiquitin–proteasome system. This could be carried out through
cooperation with various chromatin modiﬁers, such as G9a,
DNMTs, and HDAC1. It will be interesting to clarify whether NIRF
can ubiquitinate histones and other chromatin-associated proteins.
For the PPIN, NIRF forms complexes with the core components of
the cell cycle machinery [cyclins (A, B, D, and E), CDKs (CDK1,
CDK2, CDK4, and CDK6), and PCNA], two major tumor suppressors
(p53 and pRB), chromatin proteins, chromatin modiﬁers (HDAC1
and DNMTs), and components of the ubiquitin–proteasome system
[3,13]. In addition, NIRF ubiquitinates other nuclear proteins
[13,28]. The formation of multiple different protein complexes in
different contexts may help to target various distinct proteins for
ubiquitination.
In general, ubiquitin-mediated degradation is rapid and irre-
versible, but often transient. Protein phosphorylation is also rapid,
but reversible and mostly quite transient. The speciﬁcities of these
reactions are determined at the molecular interaction level. In con-
trast, writing and reading of the epigenetic marks are relatively
time-consuming processes. The speciﬁcity of epigenetic regulation
largely depends on the cellular context. In addition, epigenetic
marks are established during an allotted time period in early em-
bryos, and remain stable throughout life in most tissues. Eventu-
ally, combined effects of these timely and mechanistically
distinct regulations would ensure highly sophisticated controls
over every target gene/protein at the molecular level. In turn, this
would allow the establishment of extensive diversity in the net-
work architecture at the systems level. In particular, NIRF ubiquiti-
nates two G1 cyclins, while transient transfection of NIRF induces
G1 arrest [3,34]. Thus, ubiquitination of cyclins and the consequent
modulation of CDK activities represent one of the important means
of network reorganization by NIRF.
From the above discussions, it appears evident that NIRF is not
only a central factor in the network, but also a nodal point for the
cellular information ﬂows that inﬂuence diverse cellular functions.
More importantly, the NIRF gene network is supposed to have the
ability to create a large amount of distinct topologies of network
wiring that may help the diversity of Waddington’s canals
[76,89,90]. As a result, the NIRF gene network would facilitate cel-
lular decisions toward diverse directions, e.g., cell proliferation, dif-
ferentiation, death, or senescence [3,4]. Conversely, abrogation of
NIRF may impair cellular homeostasis, leading to a predisposition
to various diseases, including cancer.6. NIRF and diseases
Each of the three network modules interacting with NIRF, the
cell cycle machinery, the ubiquitin–proteasome system, and the
epigenetic system, is intimately involved in oncogenic processes
[10,58,59,91,92]. As an intermodular hub, NIRF is therefore ex-
pected to be associated with tumorigenesis. The molecular proper-
ties of NIRF described in the earlier sections favor the concept that
it negatively regulates cell proliferation. Indeed, loss of the NIRF
gene is frequently found in tumors. This is in sharp contrast to
the UHRF1 gene, which is scarcely subject to copy number altera-
tions in tumors.
Other than tumorigenesis, a possible link of NIRF with the path-
ogenesis of polyglutamine disease (Huntington’s disease) has been
proposed [28]. In this case, NIRF has been suggested to be involved
in the nuclear protein quality control (PQC) [93].
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The NIRF gene is localized to a region of chromosome 9p24 that
has been reported to be lost in numerous types of human malig-
nancies at the highest frequency (48%) among all chromosome re-
gions [94]. Indeed, we detected loss of heterozygosity of the NIRF
gene in several kinds of cancers from the stomach, colon, and
breast [3]. We further examined the copy number aberrations of
the NIRF gene by accessing the Oncomine database (http://
www.oncomine.org/) [95] for the reasons described below.
Genome-wide characterization of cancers has revealed enor-
mous diversity in the genomic aberrations in tumors among indi-
viduals [96]. For this reason, and to avoid bias, accessing wider
information resources is essential for determining the roles of a
particular gene in carcinogenesis. In addition, modern bioinformat-
ics technology has yielded strong analytic algorithms for the pur-
pose of such utilization. Cancer outlier proﬁle analysis (COPA) is
an innovative bioinformatics method that enables the identiﬁca-
tion of cancer genes with great accuracy and sensitivity [97].
Among many cancer databases (see [98] for a review), Oncomine
is implemented with COPA, and is thus suited for analyses of up-
stream genes that can lead to carcinogenesis [97].
When COPA was carried out with Oncomine, DNA copy number
loss of the NIRF gene was revealed at statistically signiﬁcant levels
in multiple kinds of malignancies originating from the brain,
breast, stomach, kidney, hematopoietic tissue, and lung (Fig. 4)
[3], while no signiﬁcant pattern of copy number alteration of the
UHRF1 gene was observed. As depicted, the canonical oncogenes
(KRAS and EGFR) and tumor suppressor genes (pRB and p53) exhib-
ited ampliﬁcation-dominant (i.e., red in most cancers) andFig. 4. Summary of a cancer outlier proﬁle analysis (COPA) [95,97] for NIRF. Dataset num
are illustrated. Dark blue and light blue indicate the top 1% and top 5% among the genes
among the genes with ampliﬁcation, respectively. The COPA shows that the NIRF gene is
blue in most cancers, and red in a few cases). This feature is compatible with those of the
most cancers). In contrast, the canonical oncogenes, KRAS and EGFR, are ampliﬁcation do
NIRF gene, the UHRF1 gene does not show a deﬁnite pattern of copy number aberrationdeletion-dominant (i.e., blue in most cancers) appearances, respec-
tively. NIRF exhibits the latter condition, i.e., COPA shows that the
NIRF gene is preferentially lost in diverse tumors, while its ampli-
ﬁcation is a rare event. This feature is compatible with those of the
classical tumor suppressor genes pRB and p53. Although UHRF1 is
upregulated in various cancers, the mechanism is different from
the canonical oncogenes KRAS and EGFR. The upregulation may
be secondary to the cell proliferation property of cancer cells, or
may be caused by some epigenetic changes such as structural
changes to the chromatin of the UHRF1 gene.
With the discovery that the NIRF gene is subject to frequent
copy number aberrations, a more detailed study was performed
using a multigene analysis in Oncomine. This analysis revealed a
recurrent microdeletion targeting NIRF in non-small cell lung car-
cinoma (NSCLC). As a result, 13.3% of cases were hemizygously de-
leted in the NIRF gene [3]. Consistently, the NIRF mRNA was
reduced at statistically signiﬁcant levels in lung adenocarcinoma
and squamous cell lung carcinoma, both of which are subtypes of
NSCLC. These ﬁndings suggest that loss of the NIRF gene is associ-
ated with tumor formation, and supports the concept that NIRF is a
tumor suppressor.
In recent years, genome-wide studies have implied an associa-
tion between the NIRF gene locus and colorectal cancer. Zanke
et al. [99] and Poynter et al. [100] showed that the single nucleo-
tide polymorphism (SNP) rs719725, which is located in the imme-
diate proximity (47 kb upstream) of the NIRF gene, is associated
with the risk of colorectal cancer. While both afﬁrmative [101]
and negative [102,103] data have been reported from replication
studies, these researches pointed out the possibility of linkage of
NIRF with cancer susceptibility. Interestingly, rs719725 is localizedbers showing signiﬁcant loss or ampliﬁcation of the copy number of the NIRF gene
with DNA loss, respectively. Dark red and light red indicate the top 1% and top 5%
preferentially lost in diverse tumors, whereas its ampliﬁcation is a rare event (i.e.,
classical tumor suppressor genes, pRB and p53, which are deletion dominant (blue in
minant (red in most cancers). Contrary to the genetic abnormalities observed in the
s.
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[3]. This indicates that rs719725 is really a target of chromosomal
aberration in a particular type of cancer. Thus, the SNP rs719725
appears to be associated with a chromosomal aberration inactivat-
ing NIRF, which may cause predisposition to multiple types of
tumors.
In line with the above observations of genomic aberrations,
Sjöblom et al. [104] and Wood et al. [105] reported a list of candi-
date cancer genes (CAN genes) that are mutated in breast and colo-
rectal cancers. NIRF was included in the list, indicating that the
coding sequence of the NIRF gene is mutated at statistically signif-
icant rates in cancers. Varley et al. [106] examined the methylation
patterns of the CAN gene promoters to determine whether they
exhibited tumor-speciﬁc methylation. It is well known that the
promoters of various tumor suppressor genes are frequently
hypermethylated [91,92]. This can cause transcriptional suppres-
sion of these tumor suppressor genes, often serving as a ‘‘second
hit’’, thereby leading to malignant transformation. They found that
the promoter of the NIRF gene exhibited frequent tumor-speciﬁc
hypermethylation in both breast (58%) and colon (50%) cancers.
These ﬁndings could suggest that inactivation of the gene is a
key step in tumorigenesis in both tissues [106]. Notably, the fre-
quency of aberrant methylation approaches the signiﬁcance of
even the most common genetic mutations, such as adenomatous
polyposis coli (APC) or p53mutations, which were reported to occur
in 40–80% of tumors [104]. This conforms to the general hypothesis
that epigenetic defects at CAN genes are more frequent than genet-
ic mutations [107]. Thus, the described observations collectively
demonstrate that the NIRF gene is inactivated at signiﬁcant rates
by either genetic or epigenetic aberrations in many types of cancer.
In addition to the gene inactivation in tumor samples, biological
data supporting the tumor suppressor role of NIRF have been re-
ported. NIRF forms complexes with the cell cycle machinery, and
ubiquitinates both cyclins D1 and E1 [3]. Consistently, transient
expression of NIRF induces G1 arrest [3,34]. Furthermore, as de-
scribed in Section 5.3, the expression proﬁle of NIRF favors the con-
cept that it belongs to the ‘‘differentiation module’’, which has a
role in promoting cell differentiation while antagonizing cell prolif-
eration. In conclusion, NIRF displays typical characteristics of a tu-
mor suppressor gene that functions at the G1/S boundary to inhibit
inappropriate cell cycle progression.
Although many reports, as well as our results, suggest that NIRF
can work as a tumor suppressor, other reports suggest that NIRF
may also have oncogenic functions. These contradictory results
are mainly from in vitro experiments using cancer cell lines. NIRF
was found in amplicons at chromosome 9p24 in human esopha-
geal and breast cancer cell lines. Knockdown of NIRF expression
inhibited the growth of breast cancer cells with ampliﬁcation. Con-
versely, ectopic overexpression of NIRF in non-tumorigenic
MCF10A cells promoted their proliferation with downregulation
of key cell-cycle inhibitors, such as p16INK4a, p21Waf1/Cip1, and
p27Kip1 [50]. Another two studies indicated that NIRF is a target
of the microRNA let-7a [108,109], which is an important tumor
suppressor [110]. NIRF is required for let-7a-mediated elevation
of p21Waf1/Cip1, and thus the growth-inhibitory effect of let-7a on
A549 lung cancer cells may be explained by let-7a-induced sup-
pression of NIRF and elevation of p21Waf1/Cip1 [108]. NIRF expres-
sion was aberrantly increased in colorectal cancer tissues and
associated with poor overall survival. Knockdown of NIRF led to re-
duced colorectal cell proliferation owing to cell cycle arrest at the
G0/G1 phase and reduced cell migration [109]. Thus, these ﬁndings
indicate tumorigenic roles of NIRF in several cancer cell lines and
tumor tissues, similar to the observation that TGF-b has tumor-
suppressive functions in some types of cancer cells and oncogenic
functions in other types of cancer cells.In summary, the above observations demonstrate that NIRF
plays a tumor suppressor role in many original tumors from pa-
tients. In contrast, it also plays an oncogenic role, albeit mainly
in in vitro experiments. This apparent contradiction may arise be-
cause NIRF is a multifunctional protein that is involved in the coor-
dination of three different network modules, the cell cycle
machinery, the ubiquitin–proteasome system, and the epigenetic
system. In view of the inherent complex nature of the NIRF gene
network, it will be difﬁcult to explore the precise roles of NIRF in
tumor biology. Conversely, the degree of controversy on this sub-
ject is a strong indication of the importance of NIRF as the chief
director of cellular decision processes toward various directions.
Thus, studying various different aspects of NIRF in tumor biology
will signiﬁcantly improve our knowledge of what the bona ﬁde bar-
rier is between normal cells and tumor cells.
In further studies, it will be beneﬁcial to consider the issues
listed below. First, the incidence of NIRF gene loss greatly exceeds
that of its ampliﬁcation in original tumors from various tissues
(Fig. 4). Such predominance probably reﬂects essential gene func-
tions in vivo. Therefore, we favor the concept that NIRF behaves
as a tumor suppressor in most tumor cases. However, given that
NIRF interacts with both the pRB and p53 tumor suppressors, NIRF
may promote tumor progression through ubiquitin-mediated deg-
radation of either of these suppressors. In addition, although NIRF
rapidly ubiquitinates cyclins D1 and E1 [3], it also (possibly later)
downregulates p16INK4a, p21Waf1/Cip1, and p27Kip1 through epigenetic
mechanisms [50]. This may cause bidirectional effects on the cell
cycle progression. Second, apparently paradoxical upregulation of
tumor suppressors (e.g., pRB [111], p14ARF [112], p16INK4a [113],
HIC1 [114], Rad51 [115], BRCA2 [115], miR-449a, and miR-449b
[116]) is often observed, reﬂecting negative-feedback loops that
constitute failsafe antiproliferative mechanisms [111,114–116].
This points out the need for a bioinformatic analysis, such as COPA,
that helps toward discrimination between speciﬁc and non-spe-
ciﬁc upregulation of mRNA [97]. Third, prolonged in vitro growth
of tumor cell lines sometimes causes loss of representativity. This
arises because of the evolution of novel genetic and epigenetic fea-
tures that support cell proliferation and survival [117]. In addition,
such situations may lead to signiﬁcant differences between the re-
sults of transient and stable transfection experiments. To overcome
the caveat of adaptation caused by stable transfection, we per-
formed transient expression experiments. In contrast to stable
transfection, transient transfection of NIRF effectively brought
about growth suppression ([3,34]; unpublished data). Finally, the
antibody speciﬁcity should be carefully taken into account for
the interpretation of results. We have created mouse monoclonal
antibodies that show no cross-reactivity against UHRF1 (manu-
script in preparation). We think that Nirf-knockout mice will pro-
vide critical information regarding the roles of Nirf in
tumorigenesis, and we are now ready for these analyses.
6.2. NIRF and neurodegenerative diseases
Huntington’s disease and its related autosomal-dominant poly-
glutamine neurodegenerative diseases are characterized by intran-
euronal accumulation of protein aggregates. The nucleus relies
entirely on the ubiquitin–proteasome system for PQC. Iwata et al.
[28] identiﬁed potential roles for NIRF in nuclear PQC. NIRF targets
nuclear polyglutamine aggregates for ubiquitin-mediated degrada-
tion, thereby rescuing cultured cells and primary neurons from
polyglutamine-induced cytotoxicity. A toxic expanded polygluta-
mine tract version of truncated huntingtin is more preferably
degraded than the non-toxic normal polyglutamine tract version.
[28]. More information is needed for how the nuclear PQC
system selectively recognizes the disease-causing aggregates. The
T. Mori et al. / FEBS Letters 586 (2012) 1570–1583 1581potential role of NIRF in such a discrimination mechanism awaits
further investigation.
Given that NIRF is well expressed in the brain [29], its function
in nuclear protein degradation may have another role in the main-
tenance of neuronal homeostasis. In terminally differentiated neu-
rons, aberrant re-entry into the cell cycle triggers neuronal death
instead of proliferation, and is a common pathway shared by some
acquired and neurodegenerative disorders [118]. NIRF may repress
the abnormal expression of cell cycle proteins through ubiquitin-
mediated degradation and/or epigenetic silencing, which may pro-
tect neurons against unwanted cell death. Thus, it can be hypoth-
esized that the abrogation of NIRF may be involved in the
pathogenesis of various neurological disorders.
6.3. NIRF and cancer diagnosis and treatment
At present, various genetic and epigenetic abnormalities of NIRF
have been found to be associated with cancer. For diagnostic pur-
poses, epigenetic abnormalities may be promising. The promoter
hypermethylation of NIRF in breast and colon cancers showed both
sensitivity and speciﬁcity, making it a strong classiﬁer of cancer
cells versus normal cells [106]. In addition, it is a good candidate
for a biomarker for distinguishing cancer subtypes or as a diagnos-
tic biomarker usable in peripheral specimens. Furthermore, genetic
aberrations involving the NIRF gene may also be a predictor of dis-
ease susceptibility. The linkage with various diseases should be
systematically analyzed with regard to SNPs, copy number altera-
tions, mutations, and expression levels of the NIRF gene.
Finally, it should be remembered that the NIRF gene network
could be associated with almost every means of cancer treatment.
Further investigations of NIRF are therefore necessary for future
improvements to our strategies for ﬁghting cancer.
7. Conclusions
The cell cycle network itself is a nodal point of the cellular com-
puting system. NIRF is a prototypical intermodular hub protein
that ensures coordination among three fundamental subnetwork
modules in the cell cycle network. Therefore, NIRF occupies a cen-
tral position not only in the cell cycle network but also in the
whole information network of the cell. Currently, many lines of
evidence have certiﬁed the association between NIRF and tumors.
Further investigations of the NIRF gene network will provide criti-
cal insights into how the cell cycle network regulates the epige-
netic landscape, thereby inﬂuencing the cellular identity and
differentiation programs, and conversely, how the epigenetic land-
scape affects the cell cycle network, thereby contributing to the
cellular decisions toward various directions, e.g., cell proliferation,
differentiation, death, and senescence. In addition, we will be able
to obtain novel insights into how the ubiquitin–proteasome sys-
tem is integrated into these cellular decision machineries.
We expect that further developments will yield an efﬁcient
molecular biology method for analyzing the multifaceted activities
of the NIRF gene network in vivo. However, the enormous com-
plexity of the dynamic network wiring will pose many new prob-
lems. First, the total understanding of such an intricate network
will critically depend on the development of systems biology. Sec-
ond, since NIRF is localized just at the branching point toward mul-
tiple cell fates, functional analyses of NIRF will be very difﬁcult. Of
course, overcoming these difﬁculties will help toward the emer-
gence of a great paradigm shift in the long run.
Hopefully, we will be able to obtain a critical understanding of
the dynamic nature of the network, which will help us to choose
the optimal network to focus on as a speciﬁc therapeutic target,
to achieve maximum beneﬁcial effects with minimum adverseeffects. We believe that joint research studies on NIRF through
molecular and systems biology will facilitate the understanding
of the pathophysiology as well as the development of therapeutic
strategies for many diseases, including neoplastic, neurological,
and immunological diseases.
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